A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel (EU-authorized) in patients with moderate to severe, active rheumatoid arthritis
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms EQUIRA
- Sponsors HEXAL; Sandoz
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 05 Apr 2017 This trial was completed in Spain, according to European Clinical Trials Database.